. . . . . . . . "The mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. In vitro receptor binding studies suggest that felbamate may be an antagonist at the strychnine-insensitive glycine-recognition site of the N-methyl-D-aspartate (NMDA) receptor-ionophore complex. Antagonism of the NMDA receptor glycine binding site may block the effects of the excitatory amino acids and suppress seizure activity. Animal studies indicate that felbamate may increase the seizure threshold and may decrease seizure spread. It is also indicated that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding."@en . "LD₅₀=5000 mg/kg (Orally in rats)"@en . . . "For use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use."@en . . . . . . . . . . . . . "Felbamatum"@en . . . . . . . . . "Felbamate is an anticonvulsant drug used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites."@en . . . . . . . . . . "* 756\u00B182 mL/kg"@en . . . . . . . . "25451-15-4"@en . . "Carbamic acid 2-phenyltrimethylene ester"@en . . "Felbamato"@en . "Carbamic acid 3-carbamoyloxy-2-phenyl-propyl ester"@en . ">90%"@en . "20-36%"@en . "Felbamate"@en . . . "Humans and other mammals"@en . "* 26 +/- 3 mL/hr/kg [single 1200 mg dose] * 30 +/- 8 mL/hr/kg [multiple daily doses of 3600 mg]"@en . "Felbamate"@en . . "2-Phenyl-1,3-propanediol dicarbamate"@en . "approved"@en . "20-23 hours"@en . " "@en . . . "# Leppik IE, Dreifuss FE, Pledger GW, Graves NM, Santilli N, Drury I, Tsay JY, Jacobs MP, Bertram E, Cereghino JJ, et al.: Felbamate for partial seizures: results of a controlled clinical trial. Neurology. 1991 Nov;41(11):1785-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1944909"@en . . . . . "Taking it after a meal may reduce the incidence of adverse effects."@en .